Literature DB >> 24239744

Antibiotics regulate the immune response in both presence and absence of lipopolysaccharide through modulation of Toll-like receptors, cytokine production and phagocytosis in vitro.

Christian Bode1, Britta Diedrich2, Stefan Muenster3, Viktoria Hentschel3, Christina Weisheit3, Kuno Rommelsheim3, Andreas Hoeft3, Rainer Meyer4, Olaf Boehm3, Pascal Knuefermann3, Georg Baumgarten3.   

Abstract

The inflammatory response to pathogen-associated molecular patterns such as lipopolysaccharide (LPS) in sepsis is mediated via Toll-like receptors (TLRs). Since TLRs also trigger various immune functions, including phagocytosis, their modulation is a promising strategy in the treatment of sepsis. As antibiotics have immunomodulatory properties, this study examined the effect of commonly used classes of antibiotics on i) the expression of TLRs and cytokines and ii) the phagocytic activity under sepsis-like conditions in vitro. This was achieved by incubating THP-1 monocytes and peripheral blood mononuclear cells (PBMCs) obtained from patients after open-heart surgery with the addition of LPS and six key antibiotics (piperacillin, doxycycline, erythromycin, moxifloxacin or gentamicin). After 24h, mRNA levels of both cytokines (IL-1β, IL-6) and TLRs (1, 2, 4, and 6) were monitored and phagocytosis was determined following coincubation with Escherichia coli. Each antibiotic differentially regulated the gene expression of the investigated TLRs and cytokines in monocytes. Erythromycin, moxifloxacin and doxycyclin displayed the strongest effects and changed mRNA-levels of the investigated genes up to 5.6-fold. Consistent with this, antibiotics and, in particular, moxifloxacin, regulated the TLR-and cytokine expression in activated PBMCs obtained from patients after open-heart surgery. Furthermore, piperacillin, doxycyclin and moxifloxacin inhibited the phagocytic activity of monocytes. Our results suggest that antibiotics regulate the immune response by modulating TLR- and cytokine expression as well as phagocytosis under septic conditions. Moxifloxacin, doxycycline and erythromycin were shown to possess the strongest immunomodulatory effects and these antibiotic classes should be considered for future immunomodulatory studies in sepsis.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Antibiotics; Cytokines; Immunomodulation; Phagocytosis; Sepsis; Toll-like receptors

Mesh:

Substances:

Year:  2013        PMID: 24239744     DOI: 10.1016/j.intimp.2013.10.025

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  15 in total

Review 1.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

2.  Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury.

Authors:  Konrad Peukert; Mario Fox; Susanne Schulz; Caroline Feuerborn; Stilla Frede; Christian Putensen; Hermann Wrigge; Beate Mareike Kümmerer; Sascha David; Benjamin Seeliger; Tobias Welte; Eicke Latz; Dennis Klinman; Christoph Wilhelm; Folkert Steinhagen; Christian Bode
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

3.  Linezolid, vancomycin and daptomycin modulate cytokine production, Toll-like receptors and phagocytosis in a human in vitro model of sepsis.

Authors:  Christian Bode; Stefan Muenster; Britta Diedrich; Sebastian Jahnert; Christina Weisheit; Folkert Steinhagen; Olaf Boehm; Andreas Hoeft; Rainer Meyer; Georg Baumgarten
Journal:  J Antibiot (Tokyo)       Date:  2015-03-04       Impact factor: 2.649

4.  Alteration of inflammatory cytokine production in primary total knee arthroplasty using antibiotic-loaded bone cement.

Authors:  Vajara Wilairatana; Peerasit Sinlapavilawan; Sittisak Honsawek; Noppachart Limpaphayom
Journal:  J Orthop Traumatol       Date:  2016-10-21

5.  Short-term effect of supplemental yeast extract without or with feed enzymes on growth performance, immune status and gut structure of weaned pigs challenged with Escherichia coli lipopolysaccharide.

Authors:  Samuel M Waititu; Fugui Yin; Rob Patterson; Juan C Rodriguez-Lecompte; Charles M Nyachoti
Journal:  J Anim Sci Biotechnol       Date:  2016-11-03

6.  Egg Production in Poultry Farming Is Improved by Probiotic Bacteria.

Authors:  Juan Manuel Peralta-Sánchez; Antonio Manuel Martín-Platero; Juan José Ariza-Romero; Miguel Rabelo-Ruiz; María Jesús Zurita-González; Alberto Baños; Sonia María Rodríguez-Ruano; Mercedes Maqueda; Eva Valdivia; Manuel Martínez-Bueno
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

7.  Toll-like receptor 2 downregulation and cytokine dysregulation predict mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Nak-Hyun Kim; Ji Yeon Sung; Yoon Jung Choi; Su-Jin Choi; Soyeon Ahn; Eunjeong Ji; Moonsuk Kim; Chung Jong Kim; Kyoung-Ho Song; Pyoeng Gyun Choe; Wan Beom Park; Eu Suk Kim; Kyoung Un Park; Nam-Joong Kim; Myoung-Don Oh; Hong Bin Kim
Journal:  BMC Infect Dis       Date:  2020-11-30       Impact factor: 3.090

8.  Pentoxifylline Alone or in Combination with Gentamicin or Vancomycin Inhibits Live Microbe-Induced Proinflammatory Cytokine Production in Human Cord Blood and Cord Blood Monocytes In Vitro.

Authors:  Esther M Speer; Elizabeth Diago-Navarro; Lukasz S Ozog; David J Dowling; Wei Hou; Mahnoor Raheel; Bettina C Fries; Ofer Levy
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 9.  Antibiotics, Inflammation, and Preterm Labor: A Missed Conclusion.

Authors:  Sedigheh Hantoushzadeh; Roghayeh Anvari Aliabad; Amir Hossein Norooznezhad
Journal:  J Inflamm Res       Date:  2020-05-25

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.